8-K: PetMed Express Announces Fiscal 2024 Third Quarter Results and Completion of Financial Restatement

PetMed Express reported an 11% increase in revenue for the third quarter of fiscal year 2024, driven by the acquisition of PetCareRx, and completed a financial restatement related to sales tax liabilities.

Summary

• PetMed Express announced its financial results for the third quarter of fiscal year 2024, which ended December 31, 2023.
• The company's net sales for the quarter were $65.3 million, an 11% increase compared to $58.9 million in the same quarter of the previous year.
• This increase was primarily due to the acquisition of PetCareRx, which offset declines in PetMeds' legacy sales.
• The company reported a net loss of $2.0 million, or $(0.10) per diluted share, for the quarter, compared to a net loss of $212 thousand, or $(0.01) per diluted share, in the prior year quarter.
• Adjusted EBITDA for the quarter was $924 thousand, down from $2.7 million in the same quarter of the previous year.
• PetMed Express completed a financial restatement related to the accounting treatment of certain prior period sales taxes from mid-2018 through mid-2022.
• The restatement resulted in a $7.8 million reduction in fiscal 2023 G&A expense and increased net income to $5.1 million, or $0.25 per diluted share.
• The company's cash on hand at December 31, 2023, was $49.4 million, and it has no debt.
• The company is now current in all of its SEC filings.

Sentiment

Score: 4

Explanation: The document presents mixed results with positive revenue growth offset by a net loss and a significant decrease in adjusted EBITDA. The financial restatement also raises concerns about past accounting practices. The sentiment is therefore cautiously negative.

Positives

• The company achieved an 11% increase in revenue for the third quarter of fiscal year 2024.
• The AutoShip & Save and PetPlus Membership programs are growing, now representing 52% of total revenue.
• The company has a strong balance sheet with $49.4 million in cash and no debt.
• The financial restatement has been completed, and the company is now current in all of its SEC filings.
• The restatement resulted in a positive adjustment to fiscal 2023 net income.

Negatives

• The company reported a net loss of $2.0 million for the third quarter of fiscal year 2024, compared to a net loss of $212 thousand in the same quarter of the previous year.
• Adjusted EBITDA decreased to $924 thousand from $2.7 million in the same quarter of the previous year.
• The company experienced a decline in legacy sales, which was offset by the acquisition of PetCareRx.
• The restatement was required due to misstatements in prior financial statements related to sales tax liabilities.

Risks

• The company's net loss increased significantly year-over-year.
• The decrease in Adjusted EBITDA indicates potential challenges in profitability.
• The company's legacy sales are declining, which could impact future revenue growth if not addressed.
• The financial restatement highlights potential weaknesses in the company's accounting practices and internal controls.
• The sales tax liability is now recorded at $24.2 million, which could impact future cash flow.

Future Outlook

The company did not provide specific forward-looking statements or guidance in this release.

Management Comments

• Christine Chambers, CFO of PetMeds, stated that the company is pleased to have completed the previously announced restatement.
• She also noted that the restatement does not impact the company's anticipated fiscal 2024 revenue, gross margins, or cash position as of December 31, 2023.
• She thanked all stakeholders for their trust and patience during the restatement period.

Industry Context

The pet medication and product market is competitive, with increasing online sales. PetMed Express's acquisition of PetCareRx is a strategic move to expand its market share and product offerings. The restatement highlights the importance of accurate accounting practices in the industry.

Comparison to Industry Standards

• PetMed Express's revenue growth of 11% is a positive sign, but the net loss and decrease in adjusted EBITDA are concerning when compared to industry leaders such as Chewy, which has shown consistent revenue growth and profitability.
• The restatement due to sales tax issues is not unique, as many online retailers have faced similar challenges with varying state tax laws. However, the magnitude of the restatement for PetMed Express is significant and may raise concerns about internal controls.
• Compared to other online pet pharmacies, PetMed Express's focus on AutoShip and membership programs is a common strategy to build customer loyalty and recurring revenue, similar to subscription models used by companies like Amazon and other e-commerce businesses.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decrease in adjusted EBITDA.
• Employees may be affected by the company's performance and any potential cost-cutting measures.
• Customers may benefit from the expanded product offerings due to the PetCareRx acquisition.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's profitability and ability to repay debts.

Next Steps

• The company will continue to focus on integrating PetCareRx and growing its AutoShip and membership programs.
• The company will need to address the decline in legacy sales and improve profitability.
• The company will need to ensure that its accounting practices and internal controls are robust to prevent future restatements.

Key Dates

Keywords

PetMed Express, Financial Results, Restatement, PetCareRx, Sales Tax, EBITDA, Revenue, Net Loss, AutoShip, PetPlus